EMS takes first steps outside the country

The EMS, national capital's largest pharmaceutical group, formalized last investment of $ 200 million in the United States, which will be made by Brace Pharma, subsidiary created by the Brazilian company in Maryland (USA), controlled by businessman Carlos Sanchez, to develop innovative medicines.
The Governor of the State of Maryland (USA), Martin O'Malley, met yesterday with Sanchez, at the headquarters of the pharmaceutical, in Hortolândia (SP), to discuss the project of the national laboratory in the US market. O'Malley, who is on an official visit to the country, also participated yesterday meeting with entrepreneurs at the headquarters of Federação das Indústrias do Estado de São Paulo (Fiesp).
The Brace Pharma was created by EMS to invest in companies developing medications to treat complex diseases. The first contribution of Brace will be done on biotech firm Gliknik, innovation focused on cancer and autoimmune diseases, with products in clinical development phase (advanced stage). The company analyzes other innovative projects to make investment in the North American market.
The subsidiary of EMS is already part of the Nord (National Organization for Rare Disorders), an Association of voluntary health organizations dedicated to helping people with rare diseases, especially of genetic origin, affecting small part of the population.
Scientific Committee. The Scientific Committee of the Brace Pharma, businessman Carlos Sanchez, President of the Board of Directors of the national group, asked the Austrian physician Eric Kandel won the Nobel Prize in medicine in 2000, in partnership with the Swede Arvid Carlsson; Samuel Broder, oncologist, researcher and former Director of the National Cancer Institute (NCI) and co-developer of the first medicines for Aids treatment; and Raymond Schinazi, professor and researcher at Emory University, creator of different medicines for Aids and hepatitis, as well as the renowned Brazilian cardiologist Jorge Kalil.
Biosimilar Drugs. EMS Group, known for being the largest producer of generic drugs from Brazil, if considered all the companies controlled by the group, is increasingly focusing its investments in innovative medicines. The pharmacist is also part of the Bionovis national laboratory, created from the joint venture between Hypermarcas, chemical and Union with 25% of Aché, slice each, to produce medicines Biosimilar.
The "SUPERLAB" national has received federal government support to develop complex medicines that are currently imported.